Atrial Fibrillation: The Rate or Rhythm Controversy Can It be Resolved on the Basis of Clinical Trial Data?

Singh BN . Atrial fibrillation following investigation of rhythm management: AFFIRM Trial Outcomes. What might be their implications for arrhythmia control. J Cardiovasc Pharmacol Therapeut 7(3):131-133, 2002

Tsang TS , Gersh BJ . Atrial fibrillation: An old disease, a new epidemic. Am J Med 113:432-435, 2002

Singh BN . Atrial fibrillation: Epidemiologic considerations and rationale for conversion and maintenance of sinus rhythm. J Cardiovasc Pharmacol Therapeut 8(1):S13-S26, 2003

The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators . A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347:185-193, 2002

Hohnloser SH , Kuck KH , Lilienthal J , for the PIAF Investigators . Rhythm versus rate control in atrial fibrillation—a randomized trial. Lancet 356:1789-1794, 2002

Van Gelder IC , Hagens VE , Bosker HA , et al for the Rate Control versus Electrical Control for Persistent Atrial Fibrillation Study Group . A comparison of rate control in patients with recurrent persistent atrial fibrillation. N Engl J Med 347:1834-1840, 2002

Singh BN , Singh SN , Reda DJ . Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 352:1861-1872, 2005

Van Gelder IC , Crijns HJ , Blanksma PK , et al . Time course of hemodynamic changes and improvement of exercise tolerance after cardioversion of chronic atrial fibrillation unassociated with cardiac valve disease. Am J Cardiol 72:560-566, 1993

Ueshima K , Myers J , Morris CK , et al . The effect of cardioversion on exercise capacity in patients with atrial fibrillation. Am Heart J 126:1021-1024, 1993

Singh BN . β-Adrenergic blockers as antiarrhythmic and antifibrillatory compounds: An overview. J Cardiovasc Pharmacol Therapeut 10(2):000-000, 2005